Skip to main content
IMMX
NASDAQ Life Sciences

Immix Biopharma Posts $35.6M Nine-Month Loss, Holds $336.3M Cash After $117.2M Raise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$8.07
Mkt Cap
$669.027M
52W Low
$3.26
52W High
$15.1
52W Position info
148% above low
Off High info
47% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IMMX has more than doubled off its 52-week low of $3.26.

Summary

Immix Biopharma reported a $35.6 million net loss for the first nine months of 2026 as G&A and R&D spending rose sharply, and ended September with $336.3 million in cash and short-term investments after its $117.2 million September offering. Management says that funds at least 12 months of operations.


Key Events · Earnings and Guidance · IMMX

  • Nine-Month Net Loss Widens to $35.6M

    Net loss for the nine months ended September 30, 2026 was $35,570,869 versus $18,750,783 a year earlier, pushing the accumulated deficit to $140,034,153.

  • Cash Reaches $336.3M After Offering

    Cash, cash equivalents and short-term investments totaled approximately $336.3 million at September 30, 2026, plus $4.6 million in long-term U.S. Treasury investments, following the $117.2 million net proceeds from the September 2026 offering at $11.00 per share.

  • Operating Spend Steps Up Sharply

    General and administrative expense rose to $22,350,139 for the nine months from $8,531,476, and research and development to $16,855,930 from $10,531,663, driven by hiring, equity awards and capital-raise related professional fees.

  • Cash Burn of $33.9M Over Nine Months

    Net cash used in operating activities was $33,870,537 for the nine months ended September 30, 2026, versus $12,900,697 a year earlier.


Analysis · IMMX · Life Sciences

Spending is ramping hard. General and administrative expense more than doubled to $22.4 million for the nine months, and research and development rose to $16.9 million, driving a $35.6 million net loss versus $18.8 million a year earlier. Against that, the September 2026 offering at $11.00 per share added $117.2 million net, lifting cash, cash equivalents and short-term investments to $336.3 million plus $4.6 million in long-term Treasuries — enough, management says, to fund operations for at least the next 12 months. The key question for holders is how fast that burn accelerates as the company moves NXC-201 toward a planned randomized Phase 3 in newly diagnosed AL amyloidosis; at the current nine-month cash burn of $33.9 million, the balance sheet buys years of runway, not quarters.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMMX was trading at $8.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $669M. The 52-week trading range was $3.26 to $15.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMMX - Latest Insights

IMMX
Nov 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.07
Real-time Price: $7.84 info
Change: -$0.230 (-3%) info
Market Cap: $649.959M info
IMMX
Sep 30, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.40
Real-time Price: $7.84 info
Change: -$2.56 (-25%) info
Market Cap: $649.959M info
IMMX
Sep 29, 2026, 7:22 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $12.15
Real-time Price: $7.84 info
Change: -$4.31 (-35%) info
Market Cap: $649.959M info
IMMX
Sep 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $7.84 info
Change: -$3.74 (-32%) info
Market Cap: $649.959M info
IMMX
Aug 07, 2026, 5:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.81
Real-time Price: $7.84 info
Change: -$1.97 (-20%) info
Market Cap: $649.959M info